11/17/2026 | Press release | Distributed by Public on 11/17/2026 14:42
FOR IMMEDIATE RELEASE
Contact:
Amy Adams
Senior Director of Communications, CIRM
[email protected]
SOUTH SAN FRANCISCO, CALIF., November 17, 2026 - Vito Imbasciani, chair of the California Institute for Regenerative Medicine (CIRM) governing board since March 2023, is retiring. He will continue to lead the board, formally called the Independent Citizen's Oversight Committee (ICOC), through January 4, 2027.
Imbasciani, who is 80, will be spending time in Los Angeles with his husband and continuing to see patients in his urologic surgery practice at Southern California Kaiser Permanente. He had been commuting two days per week to CIRM's offices in South San Francisco.
"There are toddlers running around today who wouldn't be alive without clinical trials CIRM is funding," Imbasciani said. "When I think about the patients CIRM has helped I'm so grateful, and it is all because California taxpayers decided that this state should be at the forefront in developing cell and gene therapies. The people of California created CIRM and they are why we've been able to help so many people through our clinical trials and training programs."
The CIRM board chair is elected by the ICOC from nominations made by four California constitutional officers - the controller, treasurer, lieutenant governor, and governor - and serves a six-year term. The CIRM board is composed of up to 35 California-based research and biotechnology industry leaders, patient advocates, nurses, and university and institution executives. Together they set the agency's priorities and allocate funding for cell and gene therapy research in the state with the goal of developing therapies for people in California and the world.
Funding for CIRM came from Proposition 71 in 2004, which allocated $3 billion for stem cell research, and then Proposition 14 in 2020, which allocated $5.5 billion to extend CIRM's mission to include gene therapies, to prioritize diseases of the central nervous system, and to emphasize making CIRM-funded therapies accessible and affordable to people in California.
As chair, Imbasciani oversaw a time of transition for the organization. In his four years, CIRM welcomed a new chair, vice-chair, and president, and developed a new framework for how the organization will allocate its remaining funding to have the best chance of delivering cures to the people of California. All funding concepts that are part of this new framework, formally called the Strategic Allocation Framework, were introduced during Imbasciani's time, and the board has begun approving funding for projects in several of the new concepts.
"When I look back four years to when Vito began his tenure, I'm incredibly impressed by how far we've come as an organization," said Jonathan Thomas, CIRM president and CEO and former board chair. "Vito brought a passion for service and deep knowledge of California politics, which is critical for us as a state agency."
Imbasciani has had an extensive career, largely focused on service to patients, to his country, and to the state of California. He started his career studying music, earning a doctorate from Cornell University with the support of a Fulbright award that enabled him to spend a year writing his PhD dissertation in Rome. He later earned an MD from University of Vermont College of Medicine.
Following his residency at Yale, Imbasciani served as a reservist in the U.S. Army Medical Corps and, after 9/11, as the State Surgeon for the California Army National Guard. He retires from the military after 27 years with the rank of colonel.
Imbasciani advocated for stem cell research, and for proposition 71. He was also actively involved in legislation related to patient rights, Emergency Medical Treatment and Labor Act regulations, and how the state should direct the funding streams created by statewide ballot initiatives. He served as secretary of the California Department of Veterans Affairs (CalVet) from 2015 to 2023.
"In everything he does at CIRM, Vito always puts patients first," said Maria Gonzalez Bonneville, CIRM board vice-chair. "He has been an advocate for making sure people from all over the state can access CIRM clinical trials and get the benefit of cell and gene therapies we are supporting. His warmth and enthusiasm for helping people have been a real asset to CIRM and to the board."
The California Institute for Regenerative Medicine (CIRM) is a state agency created by California voters to accelerate stem cell and gene therapies for people with unmet medical needs. Since 2004, Californians have entrusted CIRM with $8.5 billion to accelerate promising discoveries through clinical trials, train a regenerative medicine workforce, strengthen the state's biotechnology economy, and expand access to transformative therapies. Today, CIRM is pioneering new models of therapy development and accelerating medical breakthroughs that change lives - in California and around the world. For more information, visit www.cirm.ca.gov.